BeiGene, Ltd. — FY2023 Form 10-K
Business context and reporting period. The filing is BeiGene, Ltd.’s annual report for the fiscal year ended December 31, 2023 (filed February 26, 2024). BeiGene is a global oncology company with three internally developed approved medicines—BRUKINSA, TEVIMBRA and PARTRUVIX—and additional licensed products. It reported both full-year and fourth-quarter results; full-year comparisons below are versus 2022.
Financial performance and position
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $2.459 billion | $1.416 billion | +73.7% |
| Net product revenue | $2.190 billion | $1.255 billion | +74.5% |
| Collaboration revenue | $268.9 million | $161.3 million | +66.7% |
| Gross profit | $2.079 billion | $1.129 billion | +84.1% |
| Operating loss | $(1.208) billion | $(1.790) billion | Loss narrowed |
| Net loss | $(881.7) million | $(2.004) billion | Loss narrowed 56.0% |
| Operating cash flow | $(1.157) billion | $(1.497) billion | Cash use decreased |
| Capital expenditures | $561.9 million | $325.4 million | Increased |
- Products and markets: BRUKINSA revenue was $1.290 billion, up 128.5%; tislelizumab was $536.6 million, up 26.9%. BRUKINSA U.S. sales were $945.6 million, up 142.6%. China remained a significant market, contributing $1.102 billion of total revenue; the U.S. contributed $1.128 billion.
- Margins and expenses: Gross margin on product sales was 82.7%, versus 77.2% in 2022, which management attributed to revenue volume, geographic mix and lower per-unit costs at higher production volumes. R&D expense rose 8.4% to $1.779 billion; SG&A rose 17.7% to $1.505 billion, primarily reflecting commercial expansion in the U.S. and Europe.
- Liquidity and debt: Cash, cash equivalents and restricted cash totaled $3.186 billion at year-end, with $2.6 million in short-term investments. Total debt was $886.0 million, including $688.4 million current debt. Approximately $547.2 million of debt owed by the parent was due within 12 months. Management expects available cash and other sources to cover near-term obligations and projects funding for at least 12 months from issuance of the statements.
- Cash movement: Cash and restricted cash fell by $689.1 million during 2023. Financing provided $416.5 million, while investing provided $60.0 million, largely from investment maturities and sales, partly offset by capital spending.
- Non-GAAP measure: Adjusted operating loss was $752.5 million, compared with $1.420 billion in 2022. The company excludes specified items, including share-based compensation, depreciation and amortization; this measure is not a substitute for GAAP results.
Material changes and unusual items
- Fourth-quarter revenue was $634.4 million, up 66.9% year over year; fourth-quarter BRUKINSA sales were $413.0 million, up 134.6%. The supplied filing text does not provide a clear fourth-quarter net income or cash-flow value.
- Collaboration revenue included recognition of deferred revenue after BeiGene and Novartis terminated their tislelizumab and ociperlimab agreements in 2023. BeiGene regained worldwide rights to both medicines. Management expects collaboration revenue to decrease in 2024 following those terminations.
- Net other income of $307.9 million included a $362.9 million noncash gain from the BMS settlement and government subsidy income, partly offset by foreign-exchange and investment losses. The settlement returned 23.3 million BeiGene ordinary shares, which were retired; the company recorded no cash payment for the returned shares.
- The BMS settlement ended the license and supply agreement on December 31, 2023. BeiGene may continue selling existing REVLIMID and VIDAZA inventory until depleted or December 31, 2024, whichever comes first.
- Operating cash use remained substantial despite improvement. The company reported an accumulated deficit of $8.0 billion and expects future losses, although it anticipates product revenue growth outpacing operating expense growth.
Outlook, risks and contingencies
- Management expects product revenue to continue growing and to outpace operating expense growth, improving operating leverage and cash flow. The filing does not provide numerical revenue or earnings guidance.
- Management anticipated a U.S. TEVIMBRA decision for first-line ESCC on or before July 2024. The FDA was also reviewing BRUKINSA for relapsed/refractory follicular lymphoma, with a March 2024 action date stated in the filing.
- BeiGene is investing heavily in manufacturing capacity, including its Hopewell, New Jersey facility, anticipated to become operational in summer 2024. Year-end capital commitments were $333.5 million; construction in progress was $740.6 million.
- Key risks include clinical-trial and regulatory uncertainty; intense competition; reimbursement and pricing pressure, including China NRDL pricing; reliance on third-party manufacturers and distributors; foreign-exchange exposure; and changing PRC rules affecting data, human genetic resources and overseas securities offerings. The company also disclosed $4.1 billion of restricted net assets in PRC subsidiaries.
- Pharmacyclics sued BeiGene in 2023 alleging that BRUKINSA infringes a U.S. patent. The case was stayed pending a post-grant review petition filed by BeiGene; the company says it intends to defend the claims.
- The company reported effective disclosure controls and internal control over financial reporting; Ernst & Young LLP issued unqualified audit opinions on the financial statements and internal control.
Important facts for investors to verify
- How much of the improvement in net loss reflects recurring operating progress versus the noncash BMS settlement gain and other non-operating items.
- Whether BRUKINSA and TEVIMBRA growth can offset rising R&D and commercial spending, and what gross margins look like as geographic and reimbursement mix shifts.
- The timing and outcome of pending regulatory decisions, including TEVIMBRA in the U.S. and BRUKINSA in follicular lymphoma, and the clinical evidence supporting pipeline programs.
- Debt refinancing and liquidity needs: near-term maturities, continued operating cash burn, capital commitments and the use restrictions on STAR Offering proceeds.
- The filing marks that the financial statements reflect correction of an error; investors should review the related disclosure and quantify its effect, which is not clearly described in the supplied text.